TY - JOUR
T1 - A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer
AU - Roberto, Michela
AU - Romiti, Adriana
AU - Onesti, Concetta E.
AU - D'Antonio, Chiara
AU - Milano, Annalisa
AU - Falcone, Rosa
AU - Barucca, Viola
AU - Palombi, Lucia
AU - Righini, Riccardo
AU - Marchetti, Paolo
PY - 2016/2/1
Y1 - 2016/2/1
N2 - In recent years, metronomic chemotherapy, consisting of continuous administration of low doses of cytotoxic agents, has being used as rescue therapy for different tumours. The aim of this study was to retrospectively assess the efficacy and safety of low-dose metronomic, oral capecitabine in pretreated or frail patients with recurrent upper gastrointestinal tract cancer. Patients with pretreated upper gastrointestinal tract cancer or who were not candidates for standard chemotherapy because of toxicity concerns received capecitabine at 1500 mg per day continuously until disease progression or occurrence of toxicity. Forty-seven patients (25 oesophagogastric cancer, 22 pancreatobiliary cancer; 25 men, 22 women; median age 69 years, range 42-90) were included in the study. Forty-five percent of the patients had received at least two previous lines of treatment and the median number of previous treatments was 1 (range 0-5). Twelve (31.6%) patients achieved clinical benefit (one partial response, 11 stable disease), whereas nine (23.7%) patients were progression free for at least 6 months. In an exploratory analysis, there was a significant relationship between performance status and clinical benefit (hazard ratio=8.25; P=0.01). The median overall survival was 5 months. A good performance status was associated with a longer survival (hazard ratio=0.26; P
AB - In recent years, metronomic chemotherapy, consisting of continuous administration of low doses of cytotoxic agents, has being used as rescue therapy for different tumours. The aim of this study was to retrospectively assess the efficacy and safety of low-dose metronomic, oral capecitabine in pretreated or frail patients with recurrent upper gastrointestinal tract cancer. Patients with pretreated upper gastrointestinal tract cancer or who were not candidates for standard chemotherapy because of toxicity concerns received capecitabine at 1500 mg per day continuously until disease progression or occurrence of toxicity. Forty-seven patients (25 oesophagogastric cancer, 22 pancreatobiliary cancer; 25 men, 22 women; median age 69 years, range 42-90) were included in the study. Forty-five percent of the patients had received at least two previous lines of treatment and the median number of previous treatments was 1 (range 0-5). Twelve (31.6%) patients achieved clinical benefit (one partial response, 11 stable disease), whereas nine (23.7%) patients were progression free for at least 6 months. In an exploratory analysis, there was a significant relationship between performance status and clinical benefit (hazard ratio=8.25; P=0.01). The median overall survival was 5 months. A good performance status was associated with a longer survival (hazard ratio=0.26; P
KW - Advanced gastrointestinal cancer
KW - Metronomic chemotherapy
KW - Pretreated patients
UR - http://www.scopus.com/inward/record.url?scp=84952664909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952664909&partnerID=8YFLogxK
U2 - 10.1097/CAD.0000000000000308
DO - 10.1097/CAD.0000000000000308
M3 - Article
C2 - 26473528
AN - SCOPUS:84952664909
VL - 27
SP - 106
EP - 111
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
SN - 0959-4973
IS - 2
ER -